Largest biotech companies by cash on hand
Cash and cash equivalents at the end of the latest fiscal year. Short-term investments are not counted.
Amgen leads the 24 biotech companies ranked by cash on hand, at SGD 11.8B, ahead of BioNTech (SGD 11B) and Gilead Sciences (SGD 9.7B). Figures as of 18 Nov 2026, 22:37 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenSGD 11.8B
- Median
- SGD 558.2M
- Combined market value
- SGD 1.08T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Cash on hand ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | SGD 11.8B | SGD 309.5B | SGD 572.12 | 3.07% down | 34% up | ||
| 2 | BioNTechBNTX · Health Care | SGD 11B | SGD 26.6B | SGD 107.31 | 1.89% down | 16% down | ||
| 3 | Gilead SciencesGILD · Health Care | SGD 9.7B | SGD 270.1B | SGD 217.79 | 0.75% down | 33% up | ||
| 4 | argenxARGX · Health Care | SGD 4.5B | SGD 76.3B | SGD 1,213.16 | 0.66% down | 4% up | ||
| 5 | BiogenBIIB · Health Care | SGD 3.9B | SGD 47.9B | SGD 324.04 | 0.25% up | 49% up | ||
| 6 | ModernaMRNA · Health Care | SGD 3.3B | SGD 102.6B | SGD 253.64 | 4.84% down | 755% up | ||
| 7 | ImmunovantIMVT · Health Care | SGD 1.2B | SGD 8.8B | SGD 42.75 | 0.12% down | 43% up | ||
| 8 | QiagenQGEN · Health Care | SGD 1.1B | SGD 13.2B | SGD 63.88 | 0.38% down | 12% up | ||
| 9 | Neurocrine BiosciencesNBIX · Health Care | SGD 919M | SGD 21.2B | SGD 209.91 | 1.84% down | 20% up | ||
| 10 | RepligenRGEN · Health Care | SGD 729.5M | SGD 14.2B | SGD 222.55 | 6.47% up | 5% up | ||
| 11 | Krystal BiotechKRYS · Health Care | SGD 639.7M | SGD 12B | SGD 406.44 | 5.62% up | 46% up | ||
| 12 | ExelixisEXEL · Health Care | SGD 621.9M | SGD 21.5B | SGD 88.02 | 0.31% down | 63% up | ||
| 13 | Revolution MedicinesRVMD · Health Care | SGD 494.6M | SGD 44.6B | SGD 205.99 | 1.76% down | 131% up | ||
| 14 | Kymera TherapeuticsKYMR · Health Care | SGD 460.1M | SGD 13.3B | SGD 156.12 | 0.32% down | 87% up | ||
| 15 | CRISPR TherapeuticsCRSP · Health Care | SGD 448M | SGD 5B | SGD 51.80 | 0.10% up | 21% down | ||
| 16 | Scholar Rock HoldingSRRK · Health Care | SGD 417M | SGD 7.5B | SGD 61.87 | 6.48% up | 14% up | ||
| 17 | Bio-TechneTECH · Health Care | SGD 341.2M | SGD 14.7B | SGD 93.77 | 0.17% up | 26% up | ||
| 18 | Kodiak SciencesKOD · Health Care | SGD 270.5M | SGD 8.2B | SGD 126.07 | 1.04% up | 396% up | ||
| 19 | Twist BioscienceTWST · Health Care | SGD 235.9M | SGD 10.2B | SGD 149.96 | 3.88% up | 340% up | ||
| 20 | VaxcytePCVX · Health Care | SGD 224.2M | SGD 11.9B | SGD 75.43 | 1.48% down | 22% up | ||
| 21 | Halozyme TherapeuticsHALO · Health Care | SGD 172.5M | SGD 14.1B | SGD 123.47 | 0.18% down | 37% up | ||
| 22 | ImmunityBioIBRX · Health Care | SGD 113.9M | SGD 9.2B | SGD 8.64 | 7.03% up | 193% up | ||
| 23 | Adaptive BiotechnologiesADPT · Health Care | SGD 90.9M | SGD 5.9B | SGD 36.68 | 0.11% down | 88% up | ||
| 24 | CG OncologyCGON · Health Care | SGD 41.9M | SGD 9.2B | SGD 103.11 | 1.34% up | 85% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Cash on hand is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 1.2889 SGD).
Questions and answers
Which biotech companies rank first by cash on hand?
Amgen (SGD 11.8B), BioNTech (SGD 11B) and Gilead Sciences (SGD 9.7B) are the top three of the 24 biotech companies ranked by cash on hand as of 18 Nov 2026, 22:37 UTC.
How many biotech companies are in this ranking?
24 are ranked by cash on hand.
What are these biotech companies worth together?
The 24 biotech companies ranked by cash on hand have a combined market value of SGD 1.08T as of 18 Nov 2026, 22:37 UTC.
What does ranking by cash on hand measure?
Cash and cash equivalents at the end of the latest fiscal year. Short-term investments are not counted.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech companies by cash on hand”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=cash-on-hand
Underlying data: Yahoo Finance; SEC EDGAR.